Legend Biotech
LEGN
86 hedge funds and large institutions have $1.16B invested in Legend Biotech in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 11 closing their positions.
136% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 11
89% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $5.36M
52% more capital invested
Capital invested by funds: $766M → $1.16B (+$397M)
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
21% more funds holding
Funds holding: 71 → 86 (+15)
0.47% more ownership
Funds ownership: 10% → 10.46% (+0.47%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$68.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$52.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$33.2M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$25.5M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$61.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$47.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$37.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$18.4M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$9.82M |
LEGN Hedge Fund Activity: Q2 2021 in Review
86 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q2 2021, worth a combined $1.16B — up 52% from $766M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LEGN positions and 11 closed out — a net gain of 15 holders — while 26 added to existing stakes and 18 trimmed.
The largest buyer was Capital International Investors, adding an estimated $68.6M. The largest seller was Vivo Capital, cutting an estimated $61.1M.
- 86 institutional investors held Legend Biotech (LEGN) as of Q2 2021, up from 71 in Q1 2021.
- Funds reported $1.16B of Legend Biotech stock for Q2 2021, up 52% quarter-over-quarter.
- 26 funds opened new Legend Biotech positions in Q2 2021 and 11 closed out, a net change of +15 holders.
- The largest Legend Biotech buyer in Q2 2021 was Capital International Investors, an estimated $68.6M added.
- The largest Legend Biotech seller in Q2 2021 was Vivo Capital, an estimated $61.1M sold.
Based on aggregated 13F filings for Q2 2021.